Greetings, Advocates! Great news for the rheumatology community came on Feb. 9, when the Bipartisan Budget Act of 2018 was enacted. It contains several critical healthcare fixes pertinent to rheumatology. First, after hundreds of emails, meetings, letters to the editor, an op-ed, and a forceful 109-member coalition (led by the ACR and including many state…
Search results for: pediatric
The Science Behind Biosimilars
Although six biosimilar agents have now been approved by the U.S. Food & Drug Administration for use in rheumatology, scientific, clinical, economic and prescribing questions about the use of biosimilars abound. In fact, at the 2017 ACR/ARHP Annual Meeting in San Diego, Joseph Huffstutter, MD, a rheumatologist in private practice in Chattanooga, Tenn., said that…
3 Experts Discuss Bone Health
SAN DIEGO—At the 2017 ACR/ARHP Annual Meeting Nov. 3–8, experts discussed improving bone health in the U.S., gave tips on bone health disorders in pediatrics and reviewed new translational science findings for joint conservation in early osteonecrosis. E. Michael Lewiecki, MD, director of the New Mexico Clinical Research & Osteoporosis Center in Albuquerque, N.M., called…
Experts Discuss the Latest Precision Medicine Research
SAN DIEGO—In just two decades, precision medicine has gone from futuristic concept to realistic toolbox for clinical physicians. At the 2017 ACR Clinical Research Conference on Nov. 3, the Precision Medicine in Rheumatic Diseases: Hopes and Challenges lecture featured rheumatologists and experts on genetics, genomics, pharmacogenetics and big data who spoke about the latest research…
Intriguing Patient Cases Presented at the ACR Annual Meeting Thieves Market
SAN DIEGO—At the 2017 Thieves Market, held Nov. 6 at the ACR/ARHP Annual Meeting, rheumatologists from around the world presented patient cases to an audience of colleagues, who then voted via text messaging to choose the cases they felt were most perplexing or intriguing. The winner received a free 2018 Annual Meeting registration, and the…
ACGME Milestones Debated at ACR: Does the Milestones System Ask too many Questions?
Milestones are at the core of the current system designed to evaluate medical residency and fellowship programs and their participants. But are all milestones meaningful for medical education? This idea was at the center of a debate during the 2017 ACR/ARHP Annual Meeting, during which speakers explored the advantages and drawbacks of using training milestones for rheumatology fellowships…
Upadacitinib Receives Breakthrough Designation, Abatacept Use Expands in Australia & More
The FDA has designated upadacitinib a breakthrough therapy to treat adults with moderate to severe atopic dermatitis…
Potential Therapeutic Target for SpA
Innate lymphoid cells (ILCs) in the joints of patients may drive the pathology of spondyloarthritis through the production of granulocyte colony-stimulating factor (GM-CSF). A recent study found that both GM-CSF-producing CD4 T cells and the GM-CSF+ Th17 cells expressed high levels of GPR65—indicating that both GM-CSF and GPR65 may be therapeutic targets for spondyloarthritis…
2017 ACR/ARHP Honors & Awards, Part 2
SAN DIEGO—At the 2017 ACR/ARHP Annual Meeting in San Diego in November, the ACR and the ARHP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the ARHP winners about their individual contributions. In addition, we profile the new class…
Lupus B Cell Research Points Toward Targeted Therapies
SAN DIEGO—B cell signaling goes awry in many patients with systemic lupus erythematosus (SLE), triggering pathogenic autoimmune responses and clinical disease. At the Rheumatology Research Foundation’s 2017 Evelyn V. Hess Memorial Lecture, held on Nov. 5 at the ACR/ARHP Annual Meeting, researcher Ignacio Sanz, MD, discussed B cells’ role in this complex disease. Because lupus…
- « Previous Page
- 1
- …
- 62
- 63
- 64
- 65
- 66
- …
- 109
- Next Page »